Improved access to induced pluripotent stem cells for allogeneic cell therapy applications SEATTLE, WA. – JANUARY 20, 2022 – Pluristyx, Inc. Pluristyx, Inc., an advanced therapy tools and services biotechnology company, panCELLa, a privately held biotechnology company, and Implant Therapeutics, a developer of genetically-engineered stem cells, today announced they have entered into a manufacturing and […]

TORONTO, Jan. 8, 2021 /CNW/ - panCELLa's intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.    Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa's FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies.  These iPSC MSC cells

TORONTO, April 7, 2020 /CNW/ - panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and development of its technology platforms for cell therapy.  Support from NRC IRAP will go toward the research and development of a two-step

TORONTO, April 3, 2020 /CNW/ - panCELLa is pleased to announce that it has extended an exclusive license to Astellas for its proprietary cell technology addressing long-term allogeneic cell tolerance without the need for immune suppression of patients. In addition to the license, the agreement includes a research collaboration plan to test and enhance the utility and

Hamburg, Germany, and Toronto, Canada, 02 April 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms of the agreement, Evotec will receive a non-exclusive license to access panCELLa’s proprietary iPS cell lines,

MELBOURNE, Australia and TORONTO, Feb. 12, 2019 /CNW/ - Cartherics Pty Ltd ("Cartherics") and panCELLa Inc. ("panCELLa") are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy.  panCELLa will integrate their exclusive FailSafe™ technology into Cartherics' proprietary homozygous HLA haplotype cells to bring the power of

TORONTO, Nov. 14, 2018 /CNW/ - panCELLa is proud to announce the publication of "Linking a cell division and a suicide gene to define and improve cell therapy safety"  in the November 21st,  2018, issue of Nature. Cell therapies hold enormous promise of new treatment and cures for many currently devastating degenerative diseases, including diabetes, arthritis, blindness, heart and lung diseases.  "Even